Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLRX BioLineRx	$3.71 -1.6%	$4.41	$2.30 ▼ $32.26	$16.07M	1.15	40,599 shs	19,288 shs
CMND Clearmind Medicine	$1.03 +1.0%	$0.97	$0.80 ▼ $2.18	$4.35M	0.96	311,038 shs	42,216 shs
EDSA Edesa Biotech	$2.23 -1.3%	$2.14	$1.55 ▼ $5.00	$15.90M	0.27	21,987 shs	17,260 shs
MTEX Mannatech	$9.10 -8.1%	$8.85	$7.00 ▼ $16.49	$18.82M	0.84	19,493 shs	11,699 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLRX BioLineRx	-1.59%	+4.21%	-19.35%	+14.51%	-88.03%
CMND Clearmind Medicine	+0.98%	+4.36%	+5.10%	+4.04%	-8.04%
EDSA Edesa Biotech	-1.33%	+5.19%	-1.33%	+9.85%	-50.33%
MTEX Mannatech	-8.08%	+12.35%	+13.61%	-13.74%	+28.90%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLRX BioLineRx	3.3216 of 5 stars	3.8	5.0	2.2	0.0	1.3
CMND Clearmind Medicine	1.061 of 5 stars	0.0	4.0	3.0	1.7	0.0
EDSA Edesa Biotech	2.0914 of 5 stars	2.0	5.0	2.7	1.7	0.6
MTEX Mannatech	0.4537 of 5 stars	0.0	3.0	1.7	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLRX BioLineRx	3.50	Strong Buy	$26.00	600.81% Upside
CMND Clearmind Medicine	0.00	N/A	N/A	N/A
EDSA Edesa Biotech	4.00	Strong Buy	$5.00	124.22% Upside
MTEX Mannatech	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CMND, BLRX, MTEX, and EDSA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	EDSA Edesa Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$5.00
6/17/2025	BLRX BioLineRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/30/2025	BLRX BioLineRx	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/28/2025	BLRX BioLineRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLRX BioLineRx	$28.94M	0.55	N/A	N/A	$4.04 per share	0.92
CMND Clearmind Medicine	N/A	N/A	N/A	N/A	$0.73 per share	N/A
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	$0.70 per share	N/A
MTEX Mannatech	$117.87M	0.15	$1.96 per share	4.64	$3.14 per share	2.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLRX BioLineRx	-$9.22M	-$8.80	N/A	N/A	N/A	-45.34%	-54.79%	-17.36%	N/A
CMND Clearmind Medicine	-$5.26M	-$1.10	N/A	∞	N/A	N/A	-164.79%	-71.12%	9/15/2025 (Estimated)
EDSA Edesa Biotech	-$6.17M	-$1.32	N/A	N/A	N/A	N/A	-162.95%	-60.33%	N/A
MTEX Mannatech	$2.49M	-$0.10	N/A	∞	N/A	-3.46%	-48.60%	-10.70%	N/A

Latest CMND, BLRX, MTEX, and EDSA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	BLRX BioLineRx	-$0.35	-$1.00	-$0.65	-$1.00	$0.66 million	$0.30 million
8/12/2025	Q2 2025	MTEX Mannatech	N/A	-$2.27	N/A	-$2.27	N/A	$25.68 million
8/8/2025	Q3 2025	EDSA Edesa Biotech	-$0.26	-$0.25	+$0.01	-$0.25	N/A	N/A
6/12/2025	Q2 2025	CMND Clearmind Medicine	N/A	-$0.16	N/A	-$0.16	N/A	N/A
5/27/2025	Q1 2025	BLRX BioLineRx	-$0.84	$1.39	+$2.23	$1.39	$7.72 million	$11.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLRX BioLineRx	N/A	N/A	N/A	N/A	N/A
CMND Clearmind Medicine	N/A	N/A	N/A	N/A	N/A
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	N/A
MTEX Mannatech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLRX BioLineRx	0.37	2.27	2.04
CMND Clearmind Medicine	N/A	1.74	1.74
EDSA Edesa Biotech	N/A	18.96	15.72
MTEX Mannatech	0.58	1.11	0.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLRX BioLineRx	1.56%
CMND Clearmind Medicine	96.05%
EDSA Edesa Biotech	5.50%
MTEX Mannatech	12.98%

Insider Ownership

Company	Insider Ownership
BLRX BioLineRx	1.10%
CMND Clearmind Medicine	N/A
EDSA Edesa Biotech	22.60%
MTEX Mannatech	41.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLRX BioLineRx	40	4.26 million	4.22 million	Optionable
CMND Clearmind Medicine	N/A	4.27 million	N/A	Not Optionable
EDSA Edesa Biotech	20	7.04 million	5.45 million	Not Optionable
MTEX Mannatech	250	1.90 million	1.11 million	Not Optionable

CMND, BLRX, MTEX, and EDSA Headlines

Recent News About These Companies

Mannatech trading halted, volatility trading pause

August 14 at 3:56 PM | msn.com

Mannatech Reports Financial Results for Second Quarter 2025

August 12, 2025 | businesswire.com

Mannatech, Incorporated (MTEX) - Yahoo Finance

July 24, 2025 | finance.yahoo.com

Mannatech names Peter Griscom as new chief operating officer

June 27, 2025 | investing.com

Mannatech Announces Promotion of Peter Griscom to Chief Operating Officer - Morningstar

June 27, 2025 | morningstar.comM

Mannatech appoints Peter Griscom COO

June 26, 2025 | msn.com

Mannatech Announces Promotion of Peter Griscom to Chief Operating Officer

June 26, 2025 | businesswire.com

Mannatech Announces Results of Annual Shareholders’ Meeting

June 5, 2025 | finance.yahoo.com

Mannatech Announces Results of Annual Shareholders' Meeting

June 5, 2025 | businesswire.com

Mannatech Premieres Powerful New Documentary on Marathon Legend Steve Edwards

May 21, 2025 | businesswire.com

Mannatech Reports Financial Results for First Quarter 2025

May 13, 2025 | businesswire.com

Astronova outlines fiscal 2026 growth targets driven by aerospace and PI segment advancements

April 14, 2025 | msn.com

Mannatech Reports Fourth Quarter 2024 Financial Results

March 26, 2025 | businesswire.com

Mannatech Stock Soars to 52-Week High, Hits $16 Mark

January 30, 2025 | msn.com

Mannatech names Robert Toth vice chairman of the board

November 27, 2024 | markets.businessinsider.com

Mannatech Announces Appointment of Robert A. Toth as Vice Chairman of the Board of Directors

November 26, 2024 | businesswire.com

Mannatech Inc. Q3 Earnings Summary

November 13, 2024 | markets.businessinsider.com

Mannatech Reports Financial Results for Third Quarter 2024

November 12, 2024 | businesswire.com

Trading (MTEX) With Integrated Risk Controls

October 17, 2024 | news.stocktradersdaily.comN

(MTEX) Investment Analysis

October 6, 2024 | news.stocktradersdaily.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMND, BLRX, MTEX, and EDSA Company Descriptions

BioLineRx NASDAQ:BLRX

$3.71 -0.06 (-1.59%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$3.70 -0.01 (-0.30%)

As of 08/15/2025 07:56 PM Eastern

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Clearmind Medicine NASDAQ:CMND

$1.03 +0.01 (+0.98%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.01 -0.02 (-2.14%)

As of 08/15/2025 07:10 PM Eastern

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Edesa Biotech NASDAQ:EDSA

$2.23 -0.03 (-1.33%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.23 0.00 (0.00%)

As of 08/15/2025 04:04 PM Eastern

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Mannatech NASDAQ:MTEX

$9.10 -0.80 (-8.08%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$9.20 +0.10 (+1.09%)

As of 08/15/2025 06:31 PM Eastern

Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time